Literature DB >> 4943605

Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region.

.   

Abstract

In a double-blind clinical trial of clofibrate versus identical quantity of corn oil 497 patients with ischaemic heart disease were observed over a period of five years. The death rate and the rate of non-fatal infarcts were significantly less among the clofibrate group, and the difference was greatest in respect of sudden deaths and among patients who had previously suffered from angina rather than infarction.The cholesterol- and triglyceride-reducing properties of clofibrate were maintained throughout the period of the trial and side effects were very few. But the protective action of the drug against new infarcts and death bore no apparent relation to these properties.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4943605      PMCID: PMC1799703     

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  5 in total

1.  Simplified determination of the lipid components of blood serum.

Authors:  H V CONNERTY; A R BRIGGS; E H EATON
Journal:  Clin Chem       Date:  1961-02       Impact factor: 8.327

Review 2.  Classification of hyperlipidaemias and hyperlipoproteinaemias.

Authors:  J L Beaumont; L A Carlson; G R Cooper; Z Fejfar; D S Fredrickson; T Strasser
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

Review 3.  Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.

Authors:  D S Fredrickson; R I Levy; R S Lees
Journal:  N Engl J Med       Date:  1967-01-19       Impact factor: 91.245

4.  Comparison of membrane filtration and nephelometry with analytical ultracentrifugation, for the quantitative analysis of low density lipoprotein fractions.

Authors:  M C Stone; J M Thorp; G L Mills; T B Dick
Journal:  Clin Chim Acta       Date:  1970-12       Impact factor: 3.786

5.  MULTICENTRE TRIAL IN THE UNITED KINGDOM AND IRELAND OF A MIXTURE OF ETHYL CHLOROPHENOXYISOBUTYRATE AND ANDROSTERONE (ATROMID). A PRELIMINARY REPORT.

Authors:  K G GREEN; W H INMAN; J M THORP
Journal:  J Atheroscler Res       Date:  1963 Sep-Dec
  5 in total
  30 in total

1.  Lipid lowering drugs and coronary heart disease.

Authors:  P J Scott
Journal:  Drugs       Date:  1975       Impact factor: 9.546

2.  [Arteriosclerosis: a challenge for the surgeon. Prevention and postoperative care (author's transl)].

Authors:  G Rau
Journal:  Langenbecks Arch Chir       Date:  1975-11

Review 3.  Fibrates for treatment of the metabolic syndrome.

Authors:  Kevin C Maki
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

Review 4.  Management of lipid disorders in the elderly.

Authors:  D A Playford; G F Watts
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

Review 5.  Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.

Authors:  P Chrisp; N J Lewis; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

6.  Cholesterol trials and mortality.

Authors:  John B Warren; Simon B Dimmitt; Hans G Stampfer
Journal:  Br J Clin Pharmacol       Date:  2016-05-02       Impact factor: 4.335

Review 7.  Fibrates for secondary prevention of cardiovascular disease and stroke.

Authors:  Deren Wang; Bian Liu; Wendan Tao; Zilong Hao; Ming Liu
Journal:  Cochrane Database Syst Rev       Date:  2015-10-25

8.  [Drug treatment of primary hyperlipoproteinemia (author's transl)].

Authors:  G Klose; R Mordasini; G Middelhoff; J Augustin; H Greten
Journal:  Klin Wochenschr       Date:  1978-02-01

9.  The effect of dyslipidemic drugs on mortality: A meta-analysis.

Authors:  Shuchi Jain; Vikas Vaishnavi; Bhaswat S Chakraborty
Journal:  Indian J Pharmacol       Date:  2009-02       Impact factor: 1.200

Review 10.  Antithrombotic drugs: part II.

Authors:  A S Gallus; J Hirsh
Journal:  Drugs       Date:  1976       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.